(function(){var loadHandler=window['sl_{EC00A760-FAC2-48CD-8603-FA3C7FB92E6B}'];loadHandler&&loadHandler(22, '<div id="spr0_365510b"><div id="spr1_365510b" class="kern slide"><img id="img1_365510b" src="data/img9.png" width="1280px" height="720px" alt="" style="left:0px;top:0px;"/></div><div id="spr2_365510b" class="kern slide"><img id="img0_365510b" src="data/img10.png" width="1279.68" height="720" alt=""/><div id="svg3_365510b" style="left:434.873px;top:94.574px;"><svg width="80" height="600" viewBox="0 0 80 600"><g fill="none"><g><path fill="#2f5597" d="M79.75,599.576 L0,550.571 V0 L79.75,49.005 V599.576 Z" fill-rule="evenodd"/></g></g></svg></div><div id="svg7_365510b" style="left:435.111px;top:66.474px;"><svg width="51" height="580" viewBox="0 0 51 580"><g fill="none"><g><path fill="#203864" d="M50.672,552.143 L0,579.676 V27.288 L50.672,0 V552.143 Z" fill-rule="evenodd"/></g></g></svg></div><div id="svg11_365510b" style="left:66.627px;top:66.848px;"><svg width="420" height="552" viewBox="0 0 420 552"><g fill="none"><g><path fill="#203864" d="M0,0 H419.954 V552 H0 Z" fill-rule="evenodd"/></g></g></svg></div><div id="spr3_365510b" style="left:98.149px;top:103.126px;"><div style="width:0px;"><span id="txt0_365510b" data-width="223.697906" style="left:9.6px;top:169.46px;">Discussion</span></div><div style="width:0px;"><span id="txt1_365510b" data-width="133.151031" style="left:9.6px;top:227.06px;">points</span></div></div><div id="svg13_365510b" style="left:514.623px;top:141.974px;"><svg width="699" height="552" viewBox="0 0 699 552"><path fill="#4472c4" d="M0,0 h698.75 v551.354 h-698.75 Z"/></svg></div><div id="spr4_365510b" style="left:543.462px;top:221.037px;"><div style="width:0px;"><span id="txt2_365510b" class="nokern relpos" dir="auto" style="left:9.6px;top:-36.887px;">•</span> <span id="txt3_365510b" class="relpos" data-width="514.966187" style="left:23.33px;top:-41.019px;">Prioritisation on innovation/innovativeness</span></div><div style="width:0px;"><span id="txt4_365510b" data-width="403.763031" style="left:33.6px;top:-9.339px;">definition across frameworks, i.e.,</span></div><div style="width:0px;"><span id="txt5_365510b" data-width="495.830750" style="left:33.6px;top:22.341px;">policy/incentives, regulatory, HTA, payers</span></div><div style="width:0px;"><span id="txt6_365510b" class="nokern relpos" dir="auto" style="left:9.6px;top:115.731px;">•</span> <span id="txt7_365510b" class="relpos" data-width="186.169281" style="left:23.33px;top:111.598px;">Extent to which</span></div><div style="width:0px;"><span id="txt8_365510b" data-width="335.156250" style="left:225.48px;top:111.598px;">co-development is currently</span></div><div style="width:0px;"><span id="txt9_365510b" data-width="525.035156" style="left:33.6px;top:144.048px;">supported by a. scientific advice (EMA), incl.</span></div><div style="width:0px;"><span id="txt10_365510b" data-width="527.971375" style="left:33.6px;top:175.728px;">design of basket trials and overall support b.</span></div><div style="width:0px;"><span id="txt11_365510b" data-width="424.875000" style="left:33.6px;top:207.408px;">incentivisation to site-agnostic drug</span></div><div style="width:0px;"><span id="txt12_365510b" data-width="158.726563" style="left:33.6px;top:239.088px;">development</span></div><div style="width:0px;"><span id="txt13_365510b" class="nokern relpos" dir="auto" style="left:9.6px;top:332.477px;">•</span> <span id="txt14_365510b" class="relpos" data-width="574.477905" style="left:23.33px;top:328.345px;">Assumption on site-agnostic development being</span></div><div style="width:0px;"><span id="txt15_365510b" data-width="410.151062" style="left:33.6px;top:360.795px;">innovative – challenges &amp; reward?</span></div></div></div></div>', '{"s":[]}');})();